Seres Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
21,766.00
32,100.00
28,267
Cost of Goods Sold (COGS) incl. D&A
88.00
190.00
728.00
-
-
-
Gross Income
88.00
190.00
728.00
-
-
-
SG&A Expense
5,964.00
14,892.00
54,128.00
110,400.00
116,236.00
120,689
EBIT
6,052.00
15,082.00
54,856.00
92,839.00
91,395.00
100,284
Unusual Expense
8.00
1,418.00
147.00
-
-
-
Non Operating Income/Expense
-
-
-
969.00
425.00
170
Interest Expense
42.00
209.00
415.00
-
-
-
Pretax Income
6,102.00
16,709.00
54,780.00
91,579.00
89,380.00
98,942
Consolidated Net Income
6,102.00
16,709.00
54,780.00
91,579.00
89,380.00
98,942
Net Income
6,102.00
16,709.00
54,780.00
91,579.00
89,380.00
98,942
Net Income After Extraordinaries
6,102.00
16,709.00
54,780.00
91,579.00
89,380.00
98,942
Net Income Available to Common
6,977.00
18,000.00
54,780.00
91,579.00
89,380.00
98,942
EPS (Basic)
0.18
0.46
2.33
2.30
2.21
2.43
Basic Shares Outstanding
38,948.60
38,948.60
23,532.40
39,846.90
40,449.40
40,743.50
EPS (Diluted)
0.18
0.46
2.33
2.30
2.21
2.43
Diluted Shares Outstanding
38,948.60
38,948.60
23,532.40
39,846.90
40,449.40
40,743.50
EBITDA
5,964.00
14,892.00
54,128.00
88,634.00
84,136.00
92,422
Non-Operating Interest Income
-
-
638.00
2,229.00
1,590.00
1,172
Preferred Dividends
875.00
1,291.00
-
-
-
-
About Seres Therapeutics
View Profile
